Logo image of ALOPM.PA

ONCODESIGN PRECISION MEDICIN (ALOPM.PA) Stock Fundamental Analysis

Europe - EPA:ALOPM - FR001400CM63 - Common Stock

0.47 EUR
-0.01 (-1.05%)
Last: 11/21/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, ALOPM scores 2 out of 10 in our fundamental rating. ALOPM was compared to 75 industry peers in the Biotechnology industry. ALOPM has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ALOPM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ALOPM has reported negative net income.
ALOPM had negative earnings in each of the past 5 years.
ALOPM had a negative operating cash flow in each of the past 5 years.
ALOPM.PA Yearly Net Income VS EBIT VS OCF VS FCFALOPM.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

Looking at the Return On Assets, with a value of -2.18%, ALOPM is in the better half of the industry, outperforming 70.67% of the companies in the same industry.
Industry RankSector Rank
ROA -2.18%
ROE N/A
ROIC N/A
ROA(3y)-38.13%
ROA(5y)-30.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALOPM.PA Yearly ROA, ROE, ROICALOPM.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 100.25%, ALOPM belongs to the top of the industry, outperforming 98.67% of the companies in the same industry.
ALOPM's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ALOPM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.78%
GM growth 5YN/A
ALOPM.PA Yearly Profit, Operating, Gross MarginsALOPM.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALOPM has more shares outstanding
Compared to 1 year ago, ALOPM has a worse debt to assets ratio.
ALOPM.PA Yearly Shares OutstandingALOPM.PA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
ALOPM.PA Yearly Total Debt VS Total AssetsALOPM.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

ALOPM has an Altman-Z score of -1.47. This is a bad value and indicates that ALOPM is not financially healthy and even has some risk of bankruptcy.
ALOPM has a Altman-Z score (-1.47) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.47
ROIC/WACCN/A
WACCN/A
ALOPM.PA Yearly LT Debt VS Equity VS FCFALOPM.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M 4M 6M 8M 10M

2.3 Liquidity

A Current Ratio of 0.87 indicates that ALOPM may have some problems paying its short term obligations.
With a Current ratio value of 0.87, ALOPM is not doing good in the industry: 74.67% of the companies in the same industry are doing better.
ALOPM has a Quick Ratio of 0.87. This is a bad value and indicates that ALOPM is not financially healthy enough and could expect problems in meeting its short term obligations.
ALOPM has a worse Quick ratio (0.87) than 73.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.87
ALOPM.PA Yearly Current Assets VS Current LiabilitesALOPM.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.37% over the past year.
Looking at the last year, ALOPM shows a very negative growth in Revenue. The Revenue has decreased by -80.37% in the last year.
ALOPM shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -62.01% yearly.
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-80.37%
Revenue growth 3Y-62.01%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALOPM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.26% yearly.
Based on estimates for the next years, ALOPM will show a very strong growth in Revenue. The Revenue will grow by 78.65% on average per year.
EPS Next Y95%
EPS Next 2Y247.49%
EPS Next 3Y49.26%
EPS Next 5YN/A
Revenue Next Year151.06%
Revenue Next 2Y365.39%
Revenue Next 3Y78.65%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALOPM.PA Yearly Revenue VS EstimatesALOPM.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
ALOPM.PA Yearly EPS VS EstimatesALOPM.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 1 2 3 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALOPM. In the last year negative earnings were reported.
Also next year ALOPM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALOPM.PA Price Earnings VS Forward Price EarningsALOPM.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALOPM.PA Per share dataALOPM.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as ALOPM's earnings are expected to grow with 49.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y247.49%
EPS Next 3Y49.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALOPM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCODESIGN PRECISION MEDICIN

EPA:ALOPM (11/21/2025, 7:00:00 PM)

0.47

-0.01 (-1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.2%
Inst Owner ChangeN/A
Ins Owners8.7%
Ins Owner ChangeN/A
Market Cap8.55M
Revenue(TTM)7.98M
Net Income(TTM)-240.00K
Analysts84.44
Price Target2.04 (334.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.07
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.44
BVpS0
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100.25%
FCFM N/A
ROA(3y)-38.13%
ROA(5y)-30.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.78%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.87
Altman-Z -1.47
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y95%
EPS Next 2Y247.49%
EPS Next 3Y49.26%
EPS Next 5YN/A
Revenue 1Y (TTM)-80.37%
Revenue growth 3Y-62.01%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year151.06%
Revenue Next 2Y365.39%
Revenue Next 3Y78.65%
Revenue Next 5YN/A
EBIT growth 1Y21.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year106.11%
EBIT Next 3Y52.59%
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ONCODESIGN PRECISION MEDICIN / ALOPM.PA FAQ

What is the ChartMill fundamental rating of ONCODESIGN PRECISION MEDICIN (ALOPM.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALOPM.PA.


What is the valuation status for ALOPM stock?

ChartMill assigns a valuation rating of 1 / 10 to ONCODESIGN PRECISION MEDICIN (ALOPM.PA). This can be considered as Overvalued.


Can you provide the profitability details for ONCODESIGN PRECISION MEDICIN?

ONCODESIGN PRECISION MEDICIN (ALOPM.PA) has a profitability rating of 2 / 10.


What is the expected EPS growth for ONCODESIGN PRECISION MEDICIN (ALOPM.PA) stock?

The Earnings per Share (EPS) of ONCODESIGN PRECISION MEDICIN (ALOPM.PA) is expected to grow by 95% in the next year.